Eli Lilly and Company
Q1 2022 Earnings Call
Apr 28, 2022, 9:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2022 earnings call. [Operator instructions] And as a reminder, your conference is being recorded. I would now like to turn the conference over to your host, Kevin Hern. Please go ahead.
Kevin Hern -- Vice President of Investor Relations
Good morning. Thank you for joining us for Eli Lilly and Company's Q1 2020 earnings call. I'm Kevin Hern, vice president of investor relations. Joining me on today's call are: Dave Ricks, Lilly's chair and CEO; Anat Ashkenazi, chief financial officer; Dr.
Dan Skovronsky, chief scientific and medical officer; Anne White, president of Lilly Neuroscience; Ilya Yuffa, president of Lilly International; Jake Van Naarden, CEO of Loxo Oncology at Lilly and president of Lilly Oncology; Mike Mason, president of Lilly Diabetes; and Patrik Jonsson, president of Lilly Immunology and Lilly USA. We're also joined by Sara Smith, Kento Ueha, and Lauren Zierke of the investor relations team. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on Slide 3.
Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, please note that our commentary will focus on non-GAAP financial measures.
Now I'll turn the call over to Dave.
Dave Ricks -- Chairman and Chief Executive Officer
Thanks, Kevin. 2022 is off to a strong start with solid volume-driven revenue growth led by our key products and the new tirzepatide obesity data we announced this morning. We are focused on driving adoption of our newer medicines, preparing for key product launches, delivering several global submissions for potential new medicines, all the while advancing our pipeline to power the next wave of growth. We are pleased with the progress we saw in the first quarter.